AIM
CLDX icon

Acrospire Investment Management’s Celldex Therapeutics CLDX Stock Holding History

Acrospire Investment Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-162
Closed -$9K – 2235
2016
Q4 		$9K Buy
+162
New +$9.21K ﹤0.01% 1963

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Acrospire Investment Management's CLDX Position: Q1 2017 in Review

Acrospire Investment Management sold out of Celldex Therapeutics (CLDX) in Q1 2017, closing a stake of 162 shares — an estimated $9K sold.

Acrospire Investment Management first reported a position in CLDX in Q4 2016 and held it in 1 quarter. The position peaked at $9K in Q4 2016. 134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • Acrospire Investment Management reported no remaining Celldex Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 162 Celldex Therapeutics shares in Q1 2017, an estimated $9K.
  • Acrospire Investment Management first reported a position in Celldex Therapeutics in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Celldex Therapeutics position peaked at $9K in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.